Merrimack Pharmaceuticals Inc (MACK)

5.42
0.15 2.85
NASDAQ : Health Care
Prev Close 5.27
Open 5.28
Day Low/High 5.25 / 5.50
52 Wk Low/High 5.02 / 11.18
Volume 1.86M
Avg Volume 3.36M
Exchange NASDAQ
Shares Outstanding 129.62M
Market Cap 683.08M
EPS -1.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Merrimack Pharmaceuticals Breaks Above 200-Day Moving Average - Bullish for MACK

Merrimack Pharmaceuticals Breaks Above 200-Day Moving Average - Bullish for MACK

In trading on Thursday, shares of Merrimack Pharmaceuticals Inc. crossed above their 200 day moving average of $6.12, changing hands as high as $6.73 per share.

Jim Cramer's 'Mad Money' Recap: Get Your Shopping List Ready for Next Week

Jim Cramer's 'Mad Money' Recap: Get Your Shopping List Ready for Next Week

No matter who wins the election, Jim Cramer says, there are ways to make money.

Merrimack Announces Acceptance For Review Of ANDA Filed By Actavis For Generic Doxorubicin Hydrochloride Liposome Injection (aka DOXIL®)

Merrimack Announces Acceptance For Review Of ANDA Filed By Actavis For Generic Doxorubicin Hydrochloride Liposome Injection (aka DOXIL®)

Acceptance further validates Merrimack's leadership in development and manufacturing of complex liposomal formulations

Interesting MACK Put And Call Options For June 2017

Interesting MACK Put And Call Options For June 2017

Investors in Merrimack Pharmaceuticals Inc. saw new options begin trading this week, for the June 2017 expiration.

Merrimack Pharmaceuticals (MACK) Stock Drops, JPMorgan Downgrades

Merrimack Pharmaceuticals (MACK) Stock Drops, JPMorgan Downgrades

Merrimack Pharmaceuticals' (MACK) stock rating was reduced to 'neutral' at JPMorgan earlier today.

Closing Bell: Stocks Close Lower as Utilities Drop, Oil Prices Climb

Closing Bell: Stocks Close Lower as Utilities Drop, Oil Prices Climb

The first day of trading in the fourth quarter was rough as stocks declined Monday.

Stocks Close Down Though Crude Oil Settles Higher

Stocks Close Down Though Crude Oil Settles Higher

U.S. stocks closed lower on Monday amid lower construction spending, mostly strong auto sales, and better-than-expected manufacturing data. Crude oil increased and utilities lagged.

Stocks Trade Lower; Oil Closes With 1.2% Gain

Stocks Trade Lower; Oil Closes With 1.2% Gain

U.S. stocks pare losses in afternoon trading Monday as investors grapple with mixed data, but oil prices increase.

Merrimack Pharmaceuticals (MACK) Stock Drops, CEO Mulroy Resigns

Merrimack Pharmaceuticals (MACK) Stock Drops, CEO Mulroy Resigns

Merrimack Pharmaceuticals (MACK) announced today the resignation of CEO Robert Mulroy as well as a 22% reduction in its workforce.

Merrimack To Present Final Results Of Phase 3 NAPOLI-1 Study At The European Society For Medical Oncology 2016 Congress

Merrimack To Present Final Results Of Phase 3 NAPOLI-1 Study At The European Society For Medical Oncology 2016 Congress

- Final results of NAPOLI-1 study will be presented in a poster discussion session

Bullish and Bearish Reversals for the Week

Bullish and Bearish Reversals for the Week

Thermo Fisher is looking bullish, while Blue Buffalo goes the other way.

First Week of November 18th Options Trading For Merrimack Pharmaceuticals (MACK)

First Week of November 18th Options Trading For Merrimack Pharmaceuticals (MACK)

Investors in Merrimack Pharmaceuticals Inc. saw new options begin trading this week, for the November 18th expiration.

7 Stocks Under $10 Making Big Up Moves

7 Stocks Under $10 Making Big Up Moves

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Think Big on These Small Biotechs

Think Big on These Small Biotechs

New drugs give small-cap companies opportunity to expand markets and revenues.

Biotech Pop-Up Party in Full Swing

Biotech Pop-Up Party in Full Swing

The beaten-down biotech sector is making an impressive comeback. The sector seems to be rebounding after tumbling by more than 40%.

It's 'All Systems Go' for Biotech

It's 'All Systems Go' for Biotech

The sector seems to be rebounding after tumbling by more than 40%.

Trade-Ideas: Merrimack Pharmaceuticals (MACK) Is Today's Strong On High Relative Volume Stock

Trade-Ideas: Merrimack Pharmaceuticals (MACK) Is Today's Strong On High Relative Volume Stock

Trade-Ideas LLC identified Merrimack Pharmaceuticals (MACK) as a strong on high relative volume candidate

Here Are Some Small-Cap Pharma M&A Targets After Relypsa Deal

Here Are Some Small-Cap Pharma M&A Targets After Relypsa Deal

Investors may want to look at some small-cap pharma names that could be takeover targets like Relypsa.

Investors Scour Big Pharma M&A Scene for Next Big Takeover

Investors Scour Big Pharma M&A Scene for Next Big Takeover

Following Galenica's $1.5 billion bid for Relypsa, investors are beginning to search for the next target.

Merrimack Pharmaceuticals (MACK) Weak On High Volume Today

Merrimack Pharmaceuticals (MACK) Weak On High Volume Today

Trade-Ideas LLC identified Merrimack Pharmaceuticals (MACK) as a weak on high relative volume candidate

RSI Alert: Merrimack Pharmaceuticals (MACK) Now Oversold

RSI Alert: Merrimack Pharmaceuticals (MACK) Now Oversold

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

First Week of MACK August 19th Options Trading

First Week of MACK August 19th Options Trading

Investors in Merrimack Pharmaceuticals Inc. saw new options begin trading this week, for the August 19th expiration.

Merrimack To Present New Analyses Of Phase 3 NAPOLI-1 Data At The ESMO 18th World Congress On Gastrointestinal Cancer

Merrimack To Present New Analyses Of Phase 3 NAPOLI-1 Data At The ESMO 18th World Congress On Gastrointestinal Cancer

Oral presentation on Phase 3 NAPOLI-1 data will highlight the effects of the ONIVYDE® (irinotecan liposome injection) regimen on quality of life for patients with metastatic pancreatic adenocarcinoma previously treated with gemcitabine-based therapy